Forte Biosciences (FBRX) Competitors $11.16 -0.10 (-0.89%) Closing price 04:00 PM EasternExtended Trading$10.98 -0.18 (-1.65%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBRX vs. DSGN, RNAC, DRUG, NGNE, HUMA, PBYI, ACB, GLUE, FHTX, and AVIRShould you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Design Therapeutics (DSGN), Cartesian Therapeutics (RNAC), Bright Minds Biosciences (DRUG), Neurogene (NGNE), Humacyte (HUMA), Puma Biotechnology (PBYI), Aurora Cannabis (ACB), Monte Rosa Therapeutics (GLUE), Foghorn Therapeutics (FHTX), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Forte Biosciences vs. Its Competitors Design Therapeutics Cartesian Therapeutics Bright Minds Biosciences Neurogene Humacyte Puma Biotechnology Aurora Cannabis Monte Rosa Therapeutics Foghorn Therapeutics Atea Pharmaceuticals Forte Biosciences (NASDAQ:FBRX) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Which has more volatility and risk, FBRX or DSGN? Forte Biosciences has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Do analysts rate FBRX or DSGN? Forte Biosciences presently has a consensus target price of $68.00, suggesting a potential upside of 509.32%. Given Forte Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Forte Biosciences is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is FBRX or DSGN more profitable? Design Therapeutics' return on equity of -27.15% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -85.38% -72.34% Design Therapeutics N/A -27.15%-26.07% Which has preferable earnings and valuation, FBRX or DSGN? Design Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$35.48M-$16.29-0.69Design TherapeuticsN/AN/A-$49.59M-$1.12-4.72 Does the media refer more to FBRX or DSGN? In the previous week, Forte Biosciences had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Forte Biosciences and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.93 beat Forte Biosciences' score of 0.53 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in FBRX or DSGN? 77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by company insiders. Comparatively, 23.5% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryForte Biosciences beats Design Therapeutics on 8 of the 13 factors compared between the two stocks. Get Forte Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBRX vs. The Competition Export to ExcelMetricForte BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$138.72M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-0.6921.2231.5526.39Price / SalesN/A206.92382.8986.63Price / CashN/A44.2437.7259.11Price / Book1.418.0710.106.62Net Income-$35.48M-$54.08M$3.26B$265.42M7 Day Performance-5.10%3.95%3.58%3.45%1 Month Performance-3.79%3.03%3.69%0.45%1 Year PerformanceN/A6.84%37.69%19.41% Forte Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBRXForte Biosciences2.729 of 5 stars$11.16-0.9%$68.00+509.3%+83,431.2%$138.72MN/A-0.695DSGNDesign Therapeutics0.2796 of 5 stars$5.40+1.3%N/A+0.9%$303.53MN/A-4.8240News CoverageRNACCartesian Therapeutics2.5179 of 5 stars$11.28-0.4%$40.00+254.6%-23.1%$294.60M$38.91M-0.2164Positive NewsDRUGBright Minds Biosciences2.4201 of 5 stars$45.55+8.9%$83.25+82.8%+3,191.9%$294.58MN/A-48.98N/ANGNENeurogene1.9657 of 5 stars$20.45-0.3%$46.17+125.8%-45.5%$292.72M$930K-4.7490Positive NewsHUMAHumacyte2.1372 of 5 stars$1.80-4.3%$10.64+491.3%-79.1%$291.62M$1.57M-4.00150Analyst ForecastPBYIPuma Biotechnology4.0837 of 5 stars$5.01-12.6%$7.00+39.7%+95.5%$288.63M$238.06M5.11200Positive NewsHigh Trading VolumeACBAurora Cannabis0.9411 of 5 stars$5.12+0.8%N/A-18.2%$286.79M$246.72M-26.951,130Positive NewsGLUEMonte Rosa Therapeutics2.7879 of 5 stars$4.56-0.4%$15.33+236.3%-33.0%$282.86M$75.62M12.6790Positive NewsFHTXFoghorn Therapeutics3.0819 of 5 stars$5.10+2.4%$12.00+135.3%-34.2%$281.52M$22.60M-4.29120News CoverageAVIRAtea Pharmaceuticals2.4469 of 5 stars$3.53+0.9%$6.00+70.0%-8.3%$277.75MN/A-2.1970Positive News Related Companies and Tools Related Companies DSGN Competitors RNAC Competitors DRUG Competitors NGNE Competitors HUMA Competitors PBYI Competitors ACB Competitors GLUE Competitors FHTX Competitors AVIR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBRX) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access